Cancer diagnostics company Nucleix is planning to scale up commercial activities in Europe for its bladder test Bladder EpiCheck. The Israeli firm told Medtech Insight it is currently in advanced negotiations with distributors to expand the test’s commercial reach.
Go to the inbox of the email
address you just used to sign up.
Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “email@example.com”.
Click on the link inside the
email and you’re good to go.